6 Actions the Federal Government Should Take in Response to the Delta Variant
The federal government needs to find a way to forget past mistakes and misjudgments in the face of a new threat.

The court held that prohibiting electrical stimulation in some settings, but not others, runs afoul of a “practice of medicine” statutory provision.
Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of June 2021.
This post reflects on the ethical implications of FDA’s use of its emergency powers, and suggests opportunities for greater accountability moving forward.
FDA’s approval of aducanumab may run against the bioethical principles of beneficence and non-maleficence.
A Biologics License Application, or BLA, is FDA’s standard “full approval” mechanism for biological products, including therapeutics and vaccines.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of May 2021.
Patients are understandably desperate, but their needs are best served by following the science, rather than lowering the standards for drugs.